Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection

References

• Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367–1377. doi:10.1016/S0140-6736(10)61423-7
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–1911. doi:10.1001/jama.2014.3192
   PubMed Web of Science ®Google Scholar
• Fenwick EK, Man RE, Aung T, Ramulu P, Lamoureux EL. Beyond intraocular pressure: optimizing patient-reported outcomes in glaucoma. Prog Retin Eye Res. 2019;100801. doi:10.1016/j.preteyeres.2019.100801
   Web of Science ®Google Scholar
• Nuschke AC, Farrell SR, Levesque JM, Chauhan BC. Assessment of retinal ganglion cell damage in glaucomatous optic neuropathy: axon transport, injury and soma loss. Exp Eye Res. 2015;141:111–124. doi:10.1016/j.exer.2015.06.006
   PubMed Web of Science ®Google Scholar
• Honjo M, Tanihara H. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma. Jpn J Ophthalmol. 2018;62(2):109–126. doi:10.1007/s10384-018-0566-9
   PubMed Web of Science ®Google Scholar
• Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res. 2005;80(2):197–206. doi:10.1016/j.exer.2004.08.029
   PubMed Web of Science ®Google Scholar
• Pattabiraman PP, Rao PV. Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells. Am J Physiol Cell Physiol. 2010;298(3):C749–C763. doi:10.1152/ajpcell.00317.2009
   PubMed Web of Science ®Google Scholar
• Wang J, Liu X, Zhong Y. Rho/Rho-associated kinase pathway in glaucoma (review). Int J Oncol. 2013;43(5):1357–1367. doi:10.3892/ijo.2013.2100
   PubMed Web of Science ®Google Scholar
• Wecker T, Han H, Borner J, Grehn F, Schlunck G. Effects of TGF-beta2 on cadherins and beta-catenin in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2013;54(10):6456–6462. doi:10.1167/iovs.13-12669
   Web of Science ®Google Scholar
• Torrejon KY, Papke EL, Halman JR, et al. TGFbeta2-induced outflow alterations in a bioengineered trabecular meshwork are offset by a rho-associated kinase inhibitor. Sci Rep. 2016;6(1):38319. doi:10.1038/srep38319
   Web of Science ®Google Scholar
• Honjo M, Inatani M, Kido N, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol. 2001;119(8):1171–1178. doi:10.1001/archopht.119.8.1171
   PubMed Web of Science ®Google Scholar
• Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42(1):137–144.
   PubMed Web of Science ®Google Scholar
• Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42(5):1029–1037.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Ohta M, Inoue T, et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm’s canal endothelial cells. Sci Rep. 2016;6(1):19640. doi:10.1038/srep19640
   PubMed Web of Science ®Google Scholar
• Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2018;34(1–2):40–51. doi:10.1089/jop.2017.0023
   PubMed Web of Science ®Google Scholar
• Kameda T, Inoue T, Inatani M, et al. The effect of Rho-associated protein kinase inhibitor on monkey Schlemm’s canal endothelial cells. Invest Ophthalmol Vis Sci. 2012;53(6):3092–3103. doi:10.1167/iovs.11-8018
   Web of Science ®Google Scholar
• Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48(7):3216–3222. doi:10.1167/iovs.05-1617
   PubMed Web of Science ®Google Scholar
• Nishio M, Fukunaga T, Sugimoto M, et al. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes. Curr Eye Res. 2009;34(4):282–286. doi:10.1080/02713680902783763
   PubMed Web of Science ®Google Scholar
• Van de Velde S, Van Bergen T, Sijnave D, et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55(2):1006–1016. doi:10.1167/iovs.13-13157
   PubMed Web of Science ®Google Scholar
• Wang RF, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24(1):51–54. doi:10.1097/IJG.0b013e3182952213
   PubMed Web of Science ®Google Scholar
• Pattabiraman PP, Rinkoski T, Poeschla E, Proia A, Challa P, Rao PV. RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork. Am J Pathol. 2015;185(2):496–512. doi:10.1016/j.ajpath.2014.10.023
   Web of Science ®Google Scholar
• Li G, Mukherjee D, Navarro I, et al. Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol. 2016;787:20–31. doi:10.1016/j.ejphar.2016.04.002
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731–736. doi:10.1016/j.ajo.2013.05.016
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133(7):755–761. doi:10.1001/jamaophthalmol.2015.0525
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131(10):1288–1295. doi:10.1001/jamaophthalmol.2013.323
   PubMed Web of Science ®Google Scholar
• Sakamoto E, Ishida W, Sumi T, et al. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial. Sci Rep. 2019;9(1):3755. doi:10.1038/s41598-019-40255-9
   PubMed Web of Science ®Google Scholar
• Tanihara H, Kakuda T, Sano T, et al. Safety and efficacy of ripasudil in japanese patients with glaucoma or ocular hypertension: 3-month interim analysis of ROCK-J, a post-marketing surveillance study. Adv Ther. 2019;36(2):333–343. doi:10.1007/s12325-018-0863-1
   PubMed Web of Science ®Google Scholar
• Sato S, Hirooka K, Nitta E, Ukegawa K, Tsujikawa A. Additive intraocular pressure lowering effects of the rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33(9):1628–1634. doi:10.1007/s12325-016-0389-3
   Web of Science ®Google Scholar
• Saito H, Kagami S, Mishima K, Mataki N, Fukushima A, Araie M. Long-term side effects including blepharitis leading to discontinuation of ripasudil. J Glaucoma. 2019;28(4):289–293. doi:10.1097/IJG.0000000000001203
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26–e34. doi:10.1111/aos.12829
   PubMed Web of Science ®Google Scholar
• Kawara K, Kanamori A, Mori S, et al. Intraocular pressure-lowering effect of ripasudil hydrochloride hydrate and reasons for discontinuation of use in clinical practice. Int J Ophthalmol CliniRes. 2018;5(1):083.
   Google Scholar
• Kusakabe M, Imai Y, Natsuaki M, Yamanishi K. Allergic contact dermatitis due to ripasudil hydrochloride hydrate in eye-drops: a case report. Acta Derm Venereol. 2018;98(2):278–279. doi:10.2340/00015555-2832
   Web of Science ®Google Scholar
• Inoue K, Ishida K, Tomita G. Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil. Jpn J Ophthalmol. 2018;62(4):508–516. doi:10.1007/s10384-018-0599-0
   Web of Science ®Google Scholar
• Kusuhara S, Katsuyama A, Matsumiya W, Nakamura M. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):809–814. doi:10.1007/s00417-018-3933-9
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93(4):e254–e260. doi:10.1111/aos.12599
   PubMed Web of Science ®Google Scholar
• Inoue K, Okayama R, Shiokawa M, Ishida K, Tomita G. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure. Int Ophthalmol. 2018;38(1):93–98. doi:10.1007/s10792-016-0427-9
   Web of Science ®Google Scholar
• Inazaki H, Kobayashi S, Anzai Y, et al. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy. J Glaucoma. 2017;26(2):96–100. doi:10.1097/IJG.0000000000000552
   Web of Science ®Google Scholar
• Inazaki H, Kobayashi S, Anzai Y, et al. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol. 2017;255(10):2009–2015. doi:10.1007/s00417-017-3727-5
   Web of Science ®Google Scholar
• Yasuda M, Takayama K, Kanda T, Taguchi M, Someya H, Takeuchi M. Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension. PLoS One. 2017;12(10):e0185305. doi:10.1371/journal.pone.0185305
   PubMed Web of Science ®Google Scholar
• Komizo T, Ono T, Yagi A, Miyata K, Aihara M. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma. Jpn J Ophthalmol. 2019;63(1):40–45. doi:10.1007/s10384-018-0635-0
   Web of Science ®Google Scholar
• Tan P, Malhotra R. Oculoplastic considerations in patients with glaucoma. Surv Ophthalmol. 2016;61(6):718–725. doi:10.1016/j.survophthal.2016.03.008
   PubMed Web of Science ®Google Scholar
• Miki T, Naito T, Fujiwara M, et al. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS One. 2017;12(7):e0181550. doi:10.1371/journal.pone.0181550
   PubMed Web of Science ®Google Scholar
• Tanna AP, Johnson M. Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. Ophthalmology. 2018;125(11):1741–1756. doi:10.1016/j.ophtha.2018.04.040
   PubMed Web of Science ®Google Scholar
• Minami Y, Song YS, Ishibazawa A, et al. Effect of ripasudil on diabetic macular edema. Sci Rep. 2019;9(1):3703. doi:10.1038/s41598-019-40194-5
   Web of Science ®Google Scholar
• Wada Y, Higashide T, Nagata A, Sugiyama K. Effects of ripasudil, a rho kinase inhibitor, on blood flow in the optic nerve head of normal rats. Graefes Arch Clin Exp Ophthalmol. 2019;257(2):303–311. doi:10.1007/s00417-018-4191-6
   Web of Science ®Google Scholar
• Matsumura R, Inoue K, Shiokawa M, et al. Changes in corneal endothelial cell shape after treatment with one drop of ROCK inhibitor. Int Ophthalmol. 2020;40(2):411–417. doi:10.1007/s10792-019-01198-2
   Web of Science ®Google Scholar